RACK1 Promotes Meningioma Progression by Activation of NF-κB Pathway via Preventing CSNK2B from Ubiquitination...

Area of Science:

• Neuro-oncology
• Molecular Biology
• Cancer Research

Background:

• Higher-grade meningiomas (WHO grade II and III) exhibit aggressive behavior and high recurrence rates.
• Current treatments lack definitive pharmacological strategies for malignant meningiomas.

Purpose of the Study:

• To elucidate the molecular mechanisms driving malignant progression in meningiomas.
• To identify potential therapeutic targets for inhibiting meningioma malignancy.

Main Methods:

• Utilized protein immunoprecipitation, mass spectrometry, RNA interference, and transcriptome sequencing in meningioma cell lines (IOMM-LEE, CH157-MN).
• Conducted in vivo experiments using nude mice models.
• Investigated the role of receptor for activated C kinase 1 (RACK1) and its interaction with casein kinase 2 beta (CSNK2B).

Main Results:

• A positive correlation was observed between meningioma malignancy and RACK1 levels.
• RACK1 was found to inhibit the ubiquitination and degradation of CSNK2B, leading to CK2 activation.
• Activated CK2 promotes the NF-κb pathway, upregulating CDK4 and cyclin D3, driving cell cycle progression to G2/M phase.
• Harringtonolide (HA), a RACK1 inhibitor, significantly reduced meningioma cell malignancy.

Conclusions:

• RACK1 plays a crucial role in the malignant progression of meningiomas.
• Targeting RACK1 represents a promising therapeutic strategy for managing malignant meningiomas.